| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM199707173370301 |
| P953 | full work available at URL | https://doi.org/10.1056/nejm199707173370301 |
| http://www.nejm.org/doi/pdf/10.1056/NEJM199707173370301 | ||
| P698 | PubMed publication ID | 9219699 |
| P50 | author | Larry Moreland | Q89380794 |
| P2093 | author name string | S. Cohen | |
| W. J. Koopman | |||
| A. L. Weaver | |||
| M. B. Widmer | |||
| M. H. Schiff | |||
| R. M. Fleischmann | |||
| R. E. Ettlinger | |||
| K. Mohler | |||
| S. W. Baumgartner | |||
| E. A. Tindall | |||
| C. M. Blosch | |||
| P2860 | cites work | Matrix (Stuttgart, Germany). Supplement | Q27710112 |
| Journal of Acquired Immune Deficiency Syndromes | Q6294722 | ||
| The Journal of Rheumatology | Q7743623 | ||
| Soluble tumor necrosis factor receptors in human inflammatory synovial fluids | Q72960093 | ||
| Tumour necrosis factor soluble receptors behave as acute phase reactants following surgery in patients with rheumatoid arthritis, chronic osteomyelitis and osteoarthritis | Q72963493 | ||
| Clinical Research | Q27710467 | ||
| The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
| Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis | Q28239197 | ||
| Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures | Q28317253 | ||
| The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis results of two metaanalyses | Q29542806 | ||
| Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor | Q33903826 | ||
| A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins | Q33909940 | ||
| The mortality of rheumatoid arthritis | Q34338843 | ||
| Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage | Q34565880 | ||
| Cytokines in autoimmunity | Q35605060 | ||
| Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1 | Q36351905 | ||
| The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis | Q39475952 | ||
| Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis | Q40587405 | ||
| The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials | Q40914450 | ||
| High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia | Q41020010 | ||
| Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia | Q41020476 | ||
| Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha | Q41086253 | ||
| Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis | Q42694138 | ||
| Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis | Q44064388 | ||
| Soluble tumor necrosis factor receptors correlate with parasitemia and disease severity in human malaria | Q47850016 | ||
| Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α | Q56813295 | ||
| Evidence of Participation of the Soluble Tumor Necrosis Factor Receptor I in the Host Response to Intrauterine Infection in Preterm Labor | Q58778470 | ||
| Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases | Q61628153 | ||
| Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. | Q64971287 | ||
| High concentrations of soluble tumor necrosis factor receptors in ascites | Q67494849 | ||
| Plasma tumor necrosis factor soluble receptors in chronic renal failure | Q67504828 | ||
| Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis | Q68028260 | ||
| The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis | Q68109843 | ||
| Efficacy of low-dose methotrexate in rheumatoid arthritis | Q69884411 | ||
| Isolation and characterization of a tumor necrosis factor binding protein from urine | Q69963085 | ||
| Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum | Q70399995 | ||
| Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy | Q70468084 | ||
| The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells | Q70489695 | ||
| Evaluation of recombinant human soluble dimeric tumor necrosis factor receptor for prevention of OKT3-associated acute clinical syndrome | Q70999058 | ||
| Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients | Q72336563 | ||
| Unraveling function in the TNF ligand and receptor families | Q72393346 | ||
| Serum levels of p60 soluble tumor necrosis factor receptor during acute Kawasaki disease | Q72405365 | ||
| Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures | Q72631859 | ||
| Increased levels of intercellular adhesion molecule-1 (ICAM-1) and tumor necrosis factor receptor in the cerebrospinal fluid of patients with multiple sclerosis | Q72643563 | ||
| Increased levels of soluble tumor necrosis factor-alpha receptors in serum from pregnant women and in serum and urine samples from newborns | Q72949658 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| tumor necrosis factor receptor | Q2579343 | ||
| CD antigens | Q66660268 | ||
| P304 | page(s) | 141-147 | |
| P577 | publication date | 1997-07-01 | |
| 1997-07-17 | |||
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein | |
| Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)–Fc Fusion Protein | |||
| P478 | volume | 337 |
| Q35126551 | 15-deoxy-delta(12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats |
| Q42086793 | 2-Chloroadenosine but not adenosine induces apoptosis in rheumatoid fibroblasts independently of cell surface adenosine receptor signalling |
| Q45078356 | 4-1BB-mediated immunotherapy of rheumatoid arthritis. |
| Q91938966 | A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis |
| Q35913704 | A Dual Target-directed Agent against Interleukin-6 Receptor and Tumor Necrosis Factor α ameliorates experimental arthritis |
| Q49185981 | A Pilot Dose-Finding Study of Etanercept in Rheumatoid Arthritis |
| Q44355069 | A case of cellulitis causing tissue defect during etanercept therapy |
| Q28188829 | A clinical and economic review of disease-modifying antirheumatic drugs |
| Q81786169 | A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China |
| Q50688343 | A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. |
| Q45889035 | A gene therapy approach to treatment of autoimmune disease |
| Q35638528 | A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs |
| Q36477515 | A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis |
| Q28393278 | A multi-targeted approach to suppress tumor-promoting inflammation |
| Q23915016 | A peptide from thrombospondin 1 modulates experimental erosive arthritis by regulating connective tissue growth factor |
| Q35914971 | A prospective, single-centre, randomised study evaluating the clinical, imaging and immunological depth of remission achieved by very early versus delayed Etanercept in patients with Rheumatoid Arthritis (VEDERA). |
| Q33675468 | A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial |
| Q37030689 | A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects. |
| Q54761549 | A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate. |
| Q44643741 | A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis |
| Q22004148 | ABC50, a novel human ATP-binding cassette protein found in tumor necrosis factor-alpha-stimulated synoviocytes |
| Q56896719 | Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents |
| Q41905727 | Abatacept in the treatment of rheumatoid arthritis |
| Q33782402 | Access to disease modifying treatments for rheumatoid arthritis patients |
| Q34003178 | Acquired, but not innate, immune responses to Streptococcus pneumoniae are compromised by neutralization of CD40L. |
| Q24675105 | Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials |
| Q35763157 | Adalimumab in the therapy of uveitis in childhood |
| Q42009131 | Adalimumab in the treatment of arthritis |
| Q73832073 | Adalimumab, a fully human anti-TNF-alpha monoclonal antibody, treatment does not influence experimental UV response in the skin of rheumatoid arthritis patients |
| Q34071292 | Adenoviral transgene delivery provides an approach to identifying important molecular processes in inflammation: evidence for heterogenecity in the requirement for NFkappaB in tumour necrosis factor production |
| Q45869555 | Adenovirus encoding soluble tumor necrosis factor α receptor immunoglobulin prolongs gene expression of a cotransfected reporter gene in rat lung |
| Q58064445 | Adhesion molecules in inflammatory diseases |
| Q36055449 | An overview of economic evaluations for drugs used in rheumatoid arthritis : focus on tumour necrosis factor-alpha antagonists |
| Q36271120 | Analysing the effect of novel therapies on cytokine expression in experimental arthritis |
| Q33641909 | Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists in various environments |
| Q24529081 | Ankyrin repeat and SOCS box 3 (ASB3) mediates ubiquitination and degradation of tumor necrosis factor receptor II |
| Q34216181 | Anti-TNF agents for rheumatoid arthritis |
| Q77725135 | Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: analysis of the mechanism of action predicts utility in other diseases |
| Q38344282 | Anti-TNF in rheumatoid arthritis: an overview |
| Q34999551 | Anti-TNF therapies--the hope of tomorrow |
| Q34450313 | Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases |
| Q24806847 | Anti-TNF-alpha therapy as a clinical intervention for periprosthetic osteolysis |
| Q52902407 | Anti-TNF-α Treatment: A Possible Promoter in Endogenous Uveitis? Observational Report on Six Patients: Occurrence of Uveitis Following Etanercept Treatment |
| Q81217914 | Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity |
| Q73964436 | Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis |
| Q39121469 | Anti-inflammatory evaluation and characterization of leaf extract of Ananas comosus. |
| Q34071253 | Anti-interleukin 6 receptor antibody treatment in rheumatic disease |
| Q73502964 | Anticytokine Therapy in Rheumatoid Arthritis |
| Q39946646 | Antigen-specific T cell-mediated gene therapy in collagen-induced arthritis |
| Q34074029 | Apoptosis in rheumatic diseases |
| Q36622653 | Application of cellular gene therapy for rheumatoid arthritis |
| Q77872967 | Association of the course of collagen-induced arthritis with distinct patterns of cytokine and chemokine messenger RNA expression |
| Q77769291 | Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly |
| Q37331753 | Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept |
| Q35557370 | Autoimmune aspects of cytokine and anticytokine therapies |
| Q34135558 | Averting inflammation by targeting the cytokine environment |
| Q37728305 | BF02, a recombinant TNFR2 fusion protein, alleviates adjuvant arthritis by regulating T lymphocytes in rats |
| Q40845939 | Biologic agents and immunotherapy in rheumatoid arthritis. Progress and perspective |
| Q33203294 | Biologic agents for the treatment of juvenile rheumatoid arthritis: current status |
| Q34108783 | Biologic therapies in rheumatoid arthritis |
| Q35770607 | Biologic therapies: what and when? |
| Q37087438 | Biologic treatments for systemic rheumatic diseases |
| Q35807230 | Biological agents for rheumatoid arthritis: targeting both physical function and structural damage |
| Q77627751 | Biological insights from clinical trials with anti-TNF therapy |
| Q37390458 | Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. |
| Q37290665 | Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences |
| Q38763327 | Biologics for the treatment of autoimmune renal diseases. |
| Q37761911 | Biomarkers for rheumatoid arthritis: making it personal |
| Q37718122 | Body Image and Self-Esteem in Patients with Rheumatoid Arthritis |
| Q35766007 | CCR5 deficiency mitigates the deleterious effects of tumor necrosis factor α antagonism in murine histoplasmosis |
| Q24804352 | CD44 in rheumatoid arthritis |
| Q59758980 | CNS demyelination during anti–tumor necrosis factor alpha therapy |
| Q34071308 | Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor alpha |
| Q34091766 | Case management for patients with rheumatoid arthritis |
| Q37895016 | Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years |
| Q38129722 | Changing incidence of orthopedic surgery in rheumatic disease: contributing factors. |
| Q36903356 | Characterisation of fibroblast-like synoviocytes from a murine model of joint inflammation |
| Q22010467 | Characterization of the cDNA and gene for mouse tumour necrosis factor alpha converting enzyme (TACE/ADAM17) and its location to mouse chromosome 12 and human chromosome 2p25 |
| Q30839917 | Chemically modified ribozyme targeting TNF-alpha mRNA regulates TNF-alpha and IL-6 synthesis in synovial fibroblasts of patients with rheumatoid arthritis |
| Q77627727 | Chemokines in rheumatoid arthritis |
| Q42590931 | Chemotrap-1: an engineered soluble receptor that blocks chemokine-induced migration of metastatic cancer cells in vivo |
| Q35954483 | Cia25 on rat chromosome 12 regulates severity of autoimmune arthritis induced with pristane and with collagen |
| Q30351543 | Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience. |
| Q33809743 | Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis |
| Q81091752 | Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis |
| Q37157407 | Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study |
| Q35953220 | Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis |
| Q34276019 | Combinations of conventional disease-modifying antirheumatic drugs |
| Q41199245 | Comparison of drug and cell-based delivery: engineered adult mesenchymal stem cells expressing soluble tumor necrosis factor receptor II prevent arthritis in mouse and rat animal models |
| Q36780936 | Comparison of the efficacy of biologic therapy for rheumatoid arthritis: can the clinical trials be accurately compared? |
| Q33954663 | Consensus statement on the initiation and continuation of tumour necrosis factor blocking therapies in rheumatoid arthritis |
| Q34449716 | Cooperative role of tumour necrosis factor-α, interleukin-1β and neutrophils in a novel behavioural model that concomitantly demonstrates articular inflammation and hypernociception in mice |
| Q24682970 | Crystal structure of the catalytic domain of human tumor necrosis factor-alpha-converting enzyme |
| Q35540944 | Current Status of Tumor Necrosis Factor Inhibition Strategies in the Treatment of Vasculitis |
| Q34731287 | Current and future management approaches for rheumatoid arthritis |
| Q24804893 | Current perspectives on synovitis |
| Q43870768 | Cyclosporine differentially regulates interleukin-10, interleukin-15, and tumor necrosis factor a production by rheumatoid synoviocytes |
| Q74096072 | Cytokine mRNA in the joints and draining lymph nodes of rats with adjuvant arthritis and effects of cyclosporin A |
| Q77640485 | Cytokine therapy: lessons learned and future challenges |
| Q34456715 | Cytokine-modulating strategies and newer cytokine targets for arthritis therapy |
| Q38656230 | Cytokines and Long Noncoding RNAs |
| Q34830551 | Cytokines and anti-cytokine biologicals in autoimmunity: present and future |
| Q74775107 | Cytokines and anti-cytokine therapeutic approaches to chronic heart failure |
| Q22306446 | Cytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunity |
| Q36837890 | Cytokines and the early vein graft: strategies to enhance durability |
| Q48027852 | Cytokines in rheumatoid arthritis. Potential targets for pharmacological intervention |
| Q33974537 | Cytokines in rheumatoid arthritis: trials and tribulations |
| Q27666869 | Decoy Strategies: The Structure of TL1A:DcR3 Complex |
| Q45256819 | Decrease in circulating endothelial cell adhesion molecule and thrombomodulin levels during oral iloprost treatment in rheumatoid arthritis patients: preliminary results |
| Q36364193 | Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators |
| Q36148416 | Design of effective immunotherapy for human autoimmunity |
| Q34772654 | Design of the Wegener's Granulomatosis Etanercept Trial (WGET). |
| Q73694949 | Design, synthesis and evaluation of novel azasugar-based MMP/ADAM inhibitors |
| Q74187188 | Development of anti-TNF therapy for rheumatoid arthritis |
| Q35549213 | Differential Th1/Th2 cytokine patterns in chronic arthritis: interferon gamma is highly expressed in synovium of rheumatoid arthritis compared with seronegative spondyloarthropathies |
| Q37672638 | Differential white cell count and incident type 2 diabetes: the Insulin Resistance Atherosclerosis Study |
| Q36477567 | Direct adenovirus-mediated gene transfer of interleukin 1 and tumor necrosis factor alpha soluble receptors to rabbit knees with experimental arthritis has local and distal anti-arthritic effects |
| Q44461805 | Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). |
| Q34540317 | Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies |
| Q37767159 | Do RANKL inhibitors (denosumab) affect inflammation and immunity? |
| Q33708846 | Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis? |
| Q50083992 | Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. |
| Q36797491 | Drug-induced uveitis |
| Q35780354 | Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis |
| Q33745949 | Early diagnosis and treatment of rheumatoid arthritis for improved outcomes: focus on etanercept, a new biologic response modifier |
| Q48220313 | Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment |
| Q36563395 | Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials |
| Q24803670 | Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis |
| Q77628837 | Effect of etanercept on tenosynovitis and nodules in rheumatoid arthritis |
| Q35630092 | Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients |
| Q44951728 | Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study |
| Q54779051 | Effects and mechanisms of glucosides of chaenomeles speciosa on collagen-induced arthritis in rats |
| Q78344990 | Effects of a PEGylated soluble TNF receptor type 1 (PEG sTNF-RI) on cytokine expression in adjuvant arthritis |
| Q98772480 | Efficacy and Safety of Opinercept Tumor Necrosis Factor Inhibitor Therapy for Drug-Refractory Rheumatoid Arthritis: A Randomized Clinical Trial |
| Q35554130 | Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed |
| Q33573112 | Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project |
| Q61453693 | Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis |
| Q34768442 | Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). |
| Q36503878 | Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow. |
| Q40811142 | Efficacy of adenoviral TNF alpha antisense is enhanced by a macrophage specific promoter. |
| Q35608168 | Efficacy of anti-tumor necrosis factor therapy for extra-articular manifestations in patients with ankylosing spondylitis: a meta-analysis |
| Q42603607 | Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study |
| Q36062038 | Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis |
| Q36172262 | Efficient adenoviral infection with IkappaB alpha reveals that macrophage tumor necrosis factor alpha production in rheumatoid arthritis is NF-kappaB dependent |
| Q45863651 | Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein |
| Q77507889 | Elevated levels of proinflammatory cytokines in the semen of patients with chronic prostatitis/chronic pelvic pain syndrome |
| Q34731307 | Emerging role of anti-tumor necrosis factor therapy in rheumatic diseases |
| Q42099566 | Enhanced gene transfer to arthritic joints using adeno-associated virus type 5: implications for intra-articular gene therapy |
| Q73366582 | Etanercept (Enbrel) therapy for chronic inflammatory demyelinating polyneuropathy |
| Q34071287 | Etanercept (Enbrel): update on therapeutic use |
| Q35638509 | Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis |
| Q38410039 | Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. |
| Q35637985 | Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison |
| Q24202751 | Etanercept for the treatment of rheumatoid arthritis |
| Q24248004 | Etanercept for the treatment of rheumatoid arthritis |
| Q34764213 | Etanercept in the treatment of rheumatoid arthritis |
| Q24795061 | Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious |
| Q33544594 | Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis |
| Q35551908 | Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. |
| Q35938511 | Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis |
| Q33684274 | Etanercept: a review of its use in rheumatoid arthritis |
| Q36830130 | Etanercept: a review of its use in the management of rheumatoid arthritis |
| Q34991484 | Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis |
| Q33782355 | Etanercept: therapeutic use in patients with rheumatoid arthritis |
| Q92531721 | Evaluation of the antirheumatic effects of isoflavone-free soy protein isolate and etanercept in rats with adjuvant-induced arthritis |
| Q77802837 | Evidence of phenotypic alteration as a cause of systolic dysfunction in the failing heart |
| Q29618020 | Evolving concepts of rheumatoid arthritis |
| Q45024323 | Excitatory amino acids, TNF-alpha, and chemokine levels in synovial fluids of patients with active arthropathies |
| Q73061703 | Exogenous soluble tumor necrosis factor receptor type I ameliorates murine experimental autoimmune neuritis |
| Q24792470 | Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis |
| Q37512640 | Finding the needle in the hay stack: hematopoietic stem cells in Fanconi anemia |
| Q24804432 | Functional analysis of an arthritogenic synovial fibroblast |
| Q38934355 | Functions of interleukin-34 and its emerging association with rheumatoid arthritis |
| Q34071336 | Future prospects for anti-cytokine treatment |
| Q34007141 | Gamma interferon and lipopolysaccharide interact at the level of transcription to induce tumor necrosis factor alpha expression |
| Q35624547 | Gene Expression Profile of T-cell Receptors in the Synovium, Peripheral Blood, and Thymus during the Initial Phase of Collagen-induced Arthritis |
| Q45885240 | Gene targeting by ribozyme against TNF-alpha mRNA inhibits autoimmune arthritis |
| Q35122176 | Gene therapy for arthritis |
| Q45889269 | Gene therapy in osteoarticular diseases: where are we? |
| Q24804867 | Gene therapy in rheumatoid arthritis: how to target joint destruction? |
| Q34981859 | Genetic influences on rheumatoid arthritis in African Americans |
| Q34526939 | Genetic studies, clinical heterogeneity, and disease outcome studies in rheumatoid arthritis |
| Q54806502 | Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. |
| Q37498849 | Guidelines for the use of conventional and newer disease-modifying antirheumatic drugs in elderly patients with rheumatoid arthritis |
| Q37185040 | Histone deacetylase inhibitor KBH-A42 inhibits cytokine production in RAW 264.7 macrophage cells and in vivo endotoxemia model |
| Q35605628 | Human, viral or mutant human IL-10 expressed after local adenovirus-mediated gene transfer are equally effective in ameliorating disease pathology in a rabbit knee model of antigen-induced arthritis |
| Q36292663 | IKK{beta} as a target for treatment of inflammation induced bone loss |
| Q33716470 | IL-12 as a therapeutic target for pharmacological modulation in immune-mediated and inflammatory diseases: regulation of T helper 1/T helper 2 responses |
| Q53529589 | IL-15 exacerbates collagen-induced arthritis with an enhanced CD4+ T cell response to produce IL-17. |
| Q24796707 | IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis |
| Q77807763 | IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family |
| Q38040747 | IL-23: one cytokine in control of autoimmunity |
| Q57003162 | IL1-beta and TNF-alpha induce changes in the nuclear polyphosphoinositide signalling system in osteoblasts similar to that occurring in patients with rheumatoid arthritis: an immunochemical and immunocytochemical study |
| Q36309043 | Identification of CD226 ligand on colo205 cell surface |
| Q73204426 | Identification of a selectivity determinant for inhibition of tumor necrosis factor-alpha converting enzyme by comparative modeling |
| Q62658901 | Immunoadhesins of interleukin-6 and the IL-6/soluble IL-6R fusion protein hyper-IL-6 |
| Q28554222 | Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center Cohort |
| Q90345211 | Immunogenicity of TNF-Inhibitors |
| Q38080683 | Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis |
| Q77724990 | Immunoglobulin-cytokine fusion molecules: the new generation of immunomodulating agents |
| Q33760317 | Immunomodulation of autoimmune responses with monoclonal antibodies and immunoadhesins: treatment of ocular inflammatory disease in the next millennium |
| Q37538526 | Immunopathogenesis of granulomas in chronic autoinflammatory diseases |
| Q33709280 | Immunopharmacology: anti-inflammatory therapy targeting transcription factors |
| Q34360546 | Immunotherapy for rheumatoid arthritis |
| Q77096303 | Immunotherapy of Crohn's disease |
| Q58562368 | Impact of Buffers on Colloidal Property and Aggregation Propensities of a Bispecific Antibody |
| Q37172804 | Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group |
| Q35630063 | Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden |
| Q44343787 | Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. |
| Q36336355 | In vivo imaging of autoimmune disease in model systems. |
| Q35550051 | Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors |
| Q37129859 | Indian herbal medicines: possible potent therapeutic agents for rheumatoid arthritis |
| Q30732295 | Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses |
| Q45859175 | Induction of the p16INK4a senescence gene as a new therapeutic strategy for the treatment of rheumatoid arthritis |
| Q35084908 | Infection complications associated with the use of biologic agents |
| Q35581950 | Infections and anti–tumor necrosis factor α therapy |
| Q33885648 | Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group |
| Q44477953 | Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease |
| Q36183900 | Insight into the Structural Determinants of Imidazole Scaffold-Based Derivatives as TNF-α Release Inhibitors by in Silico Explorations |
| Q85049421 | Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis Ankylosing Spondylitis |
| Q37692950 | Interactions of IgG1 CH2 and CH3 Domains with FcRn |
| Q24793971 | Interferon-beta for treatment of rheumatoid arthritis? |
| Q28212039 | Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus |
| Q36172826 | Interleukin 6 plays a key role in the development of antigen-induced arthritis |
| Q22008772 | Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response |
| Q34003088 | Intracellular and extracellular cytokine production by human mixed mononuclear cells in response to group B streptococci |
| Q34626968 | Juvenile rheumatoid arthritis: therapeutic perspectives |
| Q28206018 | Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases |
| Q38323455 | Leptin serum levels are not correlated with disease activity in patients with rheumatoid arthritis. |
| Q28343401 | Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine-chemokine axis |
| Q45863664 | Localized expression of an anti-TNF single-chain antibody prevents development of collagen-induced arthritis |
| Q35636875 | Long term safety of etanercept in elderly subjects with rheumatic diseases |
| Q60809248 | Long-term follow-up of adalimumab monotherapy for rheumatoid arthritis in Japanese patients: a report of six cases |
| Q73117771 | Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis (RA) after monoclonal anti-TNF alpha antibody therapy |
| Q40181556 | Long-term suppression of experimental arthritis following intramuscular administration of a pseudotyped AAV2/1-TNFR:Fc Vector |
| Q34764172 | Management of inflammatory arthritis around the elbow |
| Q34978711 | Management of spondyloarthropathy: new pharmacological treatment options. |
| Q43087033 | Mast cells are an important cellular source of tumour necrosis factor alpha in human intestinal tissue |
| Q33754764 | Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis. |
| Q24538980 | Medical immunology: a new journal for a new subspecialty |
| Q79319433 | Medical resource use and costs among rheumatoid arthritis patients receiving disease-modifying antirheumatic drug therapy |
| Q35182959 | Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? |
| Q37986089 | Microencapsulated drug delivery: a new approach to pro-inflammatory cytokine inhibition |
| Q37401259 | Modulation of T-cell co-stimulation in rheumatoid arthritis: clinical experience with abatacept |
| Q24682390 | Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance |
| Q36724093 | Monitoring of nonsteroidal immunosuppressive drugs in patients with lung disease and lung transplant recipients: American College of Chest Physicians evidence-based clinical practice guidelines |
| Q35026014 | Monoclonal antibodies in immune and inflammatory diseases |
| Q34236658 | Monoclonal antibody therapy |
| Q36832911 | Multiple sclerosis as a painful disease |
| Q37313761 | Myeloid-derived suppressor cells in cancer cachexia syndrome: a new explanation for an old problem. |
| Q45871000 | Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. |
| Q43713809 | N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution |
| Q37358229 | New and emerging therapies for the treatment of rheumatoid arthritis. |
| Q33884532 | New medications for use in patients with rheumatoid arthritis |
| Q33695752 | New targets for anti-inflammatory drugs |
| Q77296417 | New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress |
| Q33668883 | New therapeutic targets for rheumatoid arthritis |
| Q35210204 | New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate |
| Q34990105 | New therapies: plasmapheresis, intravenous immunoglobulin, and monoclonal antibodies |
| Q38014654 | New tools for classification and monitoring of autoimmune diseases |
| Q34560574 | New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy. |
| Q33801264 | New vessels, new approaches: angiogenesis as a therapeutic target in musculoskeletal disorders |
| Q34585191 | Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy |
| Q47126672 | Novel pathomechanisms in inflammatory neuropathies |
| Q34096275 | Novel, non-antigen-specific therapeutic approaches to autoimmune/inflammatory diseases |
| Q73313502 | Oncostatin M induces leukocyte infiltration and cartilage proteoglycan degradation in vivo in goat joints |
| Q40828764 | Opportunities for future biological therapy in SLE. |
| Q38993316 | Optimal dose of etanercept in the treatment of rheumatoid arthritis |
| Q35060233 | Optimization of protein therapeutics by directed evolution |
| Q37519964 | Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27. |
| Q35612503 | Osteoarticular Expression of Musashi-1 in an Experimental Model of Arthritis |
| Q33782360 | PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases |
| Q29620217 | PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines |
| Q34896412 | Partial protection against collagen antibody-induced arthritis in PARP-1 deficient mice |
| Q74434021 | Pathogenesis of arthritis: recent research progress |
| Q34275985 | Pathogenesis of rheumatoid arthritis. Role of B lymphocytes |
| Q93017920 | Pathogenic stromal cells as therapeutic targets in joint inflammation |
| Q35553503 | Patient preferences for treatment of rheumatoid arthritis. |
| Q74698806 | Pediatric rheumatology: autoimmune mechanisms and therapeutic strategies |
| Q46598057 | Pharmaceutical care of patients with rheumatoid and psoriatic arthritis receiving etanercept |
| Q33941431 | Pharmaceutical intervention in the JAK/STAT signaling pathway |
| Q46508793 | Pharmacokinetic-Pharmacodynamic Modeling of Apratastat: A Population-Based Approach |
| Q35198225 | Pharmacological treatment of established rheumatoid arthritis |
| Q36595134 | Pharmacological treatments for thyroid eye disease. |
| Q73086679 | Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment |
| Q74643151 | Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome |
| Q64228943 | Plant-produced recombinant Osteopontin-Fc fusion protein enhanced osteogenesis |
| Q38766163 | Platelet-rich plasma inhibits inflammatory factors and represses rheumatoid fibroblast-like synoviocytes in rheumatoid arthritis |
| Q44566796 | Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept |
| Q33511443 | Potential role of decoy B7-H4 in the pathogenesis of rheumatoid arthritis: a mouse model informed by clinical data |
| Q37134964 | Preclinical safety evaluation of recombinant adeno-associated virus 2 vector encoding human tumor necrosis factor receptor-immunoglobulin Fc fusion gene |
| Q100464889 | Predictive factors for effective selection of Interleukin-6 inhibitor and tumor necrosis factor inhibitor in the treatment of rheumatoid arthritis |
| Q37372556 | Predictors of discontinuation of tumor necrosis factor inhibitors in patients with rheumatoid arthritis. |
| Q35093804 | Preformed enzymes in mast cell granules and their potential role in allergic rhinitis |
| Q24675216 | Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7 |
| Q36243974 | Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects |
| Q30500517 | Prospective two year follow up study comparing novel and conventional imaging procedures in patients with arthritic finger joints |
| Q59804768 | Psoriasis: Classical vs. Paradoxical. The Yin-Yang of TNF and Type I Interferon |
| Q36244231 | Pulmonary fibrosis |
| Q80969477 | Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy |
| Q39947228 | Putting the brakes on arthritis: can suppressors of cytokine signaling (SOCS) suppress rheumatoid arthritis? |
| Q80397866 | Quality-of-Life Measurements in Juvenile Rheumatoid Arthritis Patients Treated with Etanercept |
| Q47861250 | Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA. |
| Q33713530 | Recombinant proteins for genetic disease. |
| Q44966729 | Refractory Wegener's granulomatosis responds to tumor necrosis factor blockade. |
| Q24805049 | Regulation and localization of endogenous human tristetraprolin |
| Q73521731 | Regulation of angiogenesis by the C-X-C chemokines interleukin-8 and epithelial neutrophil activating peptide 78 in the rheumatoid joint |
| Q28262381 | Regulation of tumour necrosis factor signalling: live or let die |
| Q37679455 | Regulatory T-cell vaccination independent of auto-antigen |
| Q37456609 | Remaining Pain in Early Rheumatoid Arthritis Patients Treated With Methotrexate |
| Q46379201 | Respiratory complications of new treatments for rheumatoid arthritis |
| Q36755055 | Resting CD4+ effector memory T cells are precursors of bystander-activated effectors: a surrogate model of rheumatoid arthritis synovial T-cell function. |
| Q59577297 | Restoration of peripheral blood natural killer and B cell levels in patients affected by rheumatoid and psoriatic arthritis during etanercept treatment |
| Q74541001 | Rheumatoid arthritis |
| Q34275998 | Rheumatoid arthritis. From bench to bedside |
| Q35612472 | Rheumatoid arthritis: regulation of synovial inflammation |
| Q82835713 | Risk of lymphoma in patients receiving antitumor necrosis factor therapy: a meta-analysis of published randomized controlled studies |
| Q36760300 | Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis |
| Q38823319 | SOCS3 revisited: a broad regulator of disease, now ready for therapeutic use? |
| Q34293579 | STAT proteins: novel molecular targets for cancer drug discovery |
| Q35999197 | Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: results from a large Japanese postmarketing surveillance study |
| Q34595156 | Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept |
| Q53454276 | Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid arthritis |
| Q33644805 | Safety of etanercept in elderly subjects with rheumatoid arthritis |
| Q24675209 | Safety of extended treatment with anakinra in patients with rheumatoid arthritis |
| Q38018879 | Scientific basis of botanical medicine as alternative remedies for rheumatoid arthritis |
| Q37063563 | Scintigraphic detection of TNF-driven inflammation by radiolabelled certolizumab pegol in patients with rheumatoid arthritis and spondyloarthritis |
| Q35351969 | Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease |
| Q38755912 | Selected cytokine pathways in rheumatoid arthritis |
| Q27660024 | Selection of a Novel and Highly Specific Tumor Necrosis Factor (TNF ) Antagonist: INSIGHT FROM THE CRYSTAL STRUCTURE OF THE ANTAGONIST-TNF COMPLEX |
| Q35804422 | Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease. |
| Q89621195 | Sensory Ganglia-Specific TNF Expression Is Associated With Persistent Nociception After Resolution of Inflammation |
| Q24804764 | Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept |
| Q78754504 | Setting the cytokine trap for autoimmunity |
| Q33782305 | Signal transduction by tumour necrosis factor and tumour necrosis factor related ligands and their receptors |
| Q41774423 | Site-directed mutagenesis of the CC chemokine binding protein 35K-Fc reveals residues essential for activity and mutations that increase the potency of CC chemokine blockade |
| Q40812961 | Soluble Kit receptor blocks stem cell factor bioactivity in vitro |
| Q77628536 | Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study |
| Q52066325 | Soluble antagonists to interleukin-1 (IL-1) and tumor necrosis factor (TNF) inhibits loss of tissue attachment in experimental periodontitis. |
| Q77118243 | Soluble tumor necrosis factor receptor (p75) fusion protein (ENBREL) as a therapy for rheumatoid arthritis |
| Q35714438 | Soluble tumor necrosis factor receptor: enbrel (etanercept) for subacute pulmonary dysfunction following allogeneic stem cell transplantation. |
| Q44585210 | Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis |
| Q36983518 | Squamous cell carcinoma of the rectum: a consequence of immunosuppression resulting from inhibiting tumour necrosis factor (TNF)? |
| Q40848438 | Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis |
| Q42813197 | Structure based optimization of chromen-based TNF-α converting enzyme (TACE) inhibitors on S1′ pocket and their quantitative structure–activity relationship (QSAR) study |
| Q44520573 | Structure--activity relationships of azasugar-based MMP/ADAM inhibitors |
| Q91163336 | Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]Pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 2 |
| Q92841691 | Structure-Based Design, Synthesis, and Biological Evaluation of Imidazo[4,5-b]pyridin-2-one-Based p38 MAP Kinase Inhibitors: Part 1 |
| Q32068329 | Structure-activity relationships of quinazoline derivatives: dual-acting compounds with inhibitory activities toward both TNF-alpha production and T cell proliferation |
| Q40602779 | Suppression of the clinical and cytokine response to endotoxin by RWJ-67657, a p38 mitogen-activated protein-kinase inhibitor, in healthy human volunteers. |
| Q44700108 | Swertia chirayita mediated modulation of interleukin-1beta, interleukin-6, interleukin-10, interferon-gamma, and tumor necrosis factor-alpha in arthritic mice |
| Q39431367 | Synovial tissue research: a state-of-the-art review |
| Q44011780 | Synthesis and bioactivities of novel 4,5,6,7-tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production |
| Q74452151 | Synthesis and bioactivities of novel bicyclic thiophenes and 4,5,6,7-tetrahydrothieno[2,3-c]pyridines as inhibitors of tumor necrosis factor-alpha (TNF-alpha) production |
| Q21134808 | Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis |
| Q34523450 | Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70 |
| Q36452687 | T-cell activation via CD26 and caveolin-1 in rheumatoid synovium |
| Q43837384 | TIA-1 regulates the production of tumor necrosis factor alpha in macrophages, but not in lymphocytes |
| Q48319094 | TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis |
| Q28972424 | TNF inhibitor therapy for rheumatoid arthritis |
| Q40556439 | TNF receptor-associated periodic syndrome (TRAPS): clinical aspects and physiopathology of a rare familial disease |
| Q64969485 | TNF-α inhibitors in the treatment of hidradenitis suppurativa. |
| Q33971049 | TNFRSF1A mutations and autoinflammatory syndromes |
| Q28140568 | Tachykinin receptors on human monocytes: their involvement in rheumatoid arthritis |
| Q41632994 | Taming TNF: strategies to restrain this proinflammatory cytokine |
| Q34436456 | Targeting tumor necrosis factor alpha. New drugs used to modulate inflammatory diseases |
| Q73128904 | Thalidomide analogue CC1069 inhibits development of rat adjuvant arthritis |
| Q35336802 | The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug |
| Q44416332 | The arthritogenic properties of microbial antigens. Their implications in disease states |
| Q35556360 | The biology of TNF blockade |
| Q24812699 | The contact-mediated response of peripheral-blood monocytes to preactivated T cells is suppressed by serum factors in rheumatoid arthritis |
| Q45869577 | The contralateral effect conferred by intra-articular adenovirus-mediated gene transfer of viral IL-10 is specific to the immunizing antigen |
| Q44428544 | The development of new triazole based inhibitors of tumor necrosis factor-α (TNF-α) production |
| Q81024281 | The effect of etanercept on Graves' ophthalmopathy: a pilot study |
| Q35636615 | The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis |
| Q79366300 | The effect of infliximab on chemokines in patients with rheumatoid arthritis |
| Q42236055 | The effects of interleukin-1beta in tumor necrosis factor-alpha-induced acute pulmonary inflammation in mice |
| Q36204163 | The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice |
| Q38056897 | The feasibility of randomized controlled trials for early arthritis therapies (Earth) involving acute anterior cruciate ligament tear cohorts |
| Q40859444 | The future role of anti-tumour necrosis factor (TNF) products in the treatment of rheumatoid arthritis |
| Q40839501 | The future role of anti-tumour necrosis factor-alpha products in the treatment of Crohn's disease |
| Q34108788 | The genetics of rheumatoid arthritis: influences on susceptibility, severity, and treatment response |
| Q34504770 | The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo |
| Q43941814 | The other side of TNF-targeted therapy of patients with rheumatoid arthritis |
| Q35205342 | The pathophysiological role of cytokines. |
| Q36434130 | The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis |
| Q33782321 | The rationale for the current boom in anti-TNFalpha treatment. Is there an effective means to define therapeutic targets for drugs that provide all the benefits of anti-TNFalpha and minimise hazards? |
| Q47115001 | The role of aberrant expression of T cell miRNAs affected by TNF-α in the immunopathogenesis of rheumatoid arthritis. |
| Q35106477 | The role of anticytokine therapy in heart failure: recent lessons from preclinical and clinical trials? |
| Q39738345 | The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis |
| Q28214190 | The role of transsignalling via the agonistic soluble IL-6 receptor in human diseases |
| Q33862430 | The role of tumor necrosis factor in the pathophysiology of heart failure |
| Q35145613 | The signaling adaptors and pathways activated by TNF superfamily |
| Q35859217 | The treatment of rheumatoid arthritis |
| Q34108762 | The treatment of rheumatoid arthritis: a review of recent clinical trials |
| Q37278012 | Therapeutic advances in rheumatology with the use of recombinant proteins |
| Q77995733 | Therapeutic antibodies elicited by immunization against TNF-alpha |
| Q82877041 | Therapeutic effects of TACI-Ig on rat with adjuvant arthritis |
| Q37129557 | Therapeutic efficacy of intra-articular adrenomedullin injection in antigen-induced arthritis in rabbits. |
| Q35140855 | Therapeutic strategies for rheumatoid arthritis |
| Q24806367 | Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches |
| Q34108776 | Therapy of rheumatoid arthritis: new developments and trends |
| Q37060528 | Thyroid-associated orbitopathy: Current insights into the pathophysiology, immunology and management. |
| Q77748079 | Toxicity antagonists in head and neck cancer |
| Q33667903 | Treatment advances in rheumatoid arthritis |
| Q53983532 | Treatment of experimental autoimmune myasthenia gravis with recombinant human tumor necrosis factor receptor Fc protein. |
| Q27758942 | Treatment of osteoarthritis with aspartame |
| Q56060521 | Treatment of rheumatoid arthritis |
| Q36300479 | Treatment of rheumatoid arthritis by molecular-targeted agents: efficacy and limitations |
| Q83980148 | Treatment of rheumatoid arthritis with ornidazole: a randomized, double-blind, placebo-controlled study |
| Q30885007 | Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense |
| Q61863535 | Treatment with monoclonal anti-tumor necrosis factor alpha antibody results in an accumulation of Th1 CD4+ T cells in the peripheral blood of patients with rheumatoid arthritis |
| Q35554567 | Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies |
| Q40845949 | Triple therapy with methotrexate, sulfasalazine, and hydroxychloroquine in patients with rheumatoid arthritis |
| Q80821536 | Tumor necrosis factor alpha -308 polymorphism is associated with rheumatoid arthritis in Han population of Eastern China |
| Q33328963 | Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety |
| Q34000190 | Tumor necrosis factor alpha receptor I is important for survival from Streptococcus pneumoniae infections. |
| Q90403909 | Tumor necrosis factor α in aGVHD patients contributed to the impairment of recipient bone marrow MSC stemness and deficiency of their hematopoiesis-promotion capacity |
| Q34276023 | Tumor necrosis factor-alpha blockade in the treatment of rheumatoid arthritis |
| Q90211848 | Tumor necrosis factor-driven cell death in donor organ as a barrier to immunological tolerance |
| Q40975748 | Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. |
| Q57079509 | Tumour necrosis factor (TNF) production by T cell receptor-primed T lymphocytes is a target for low dose methotrexate in rheumatoid arthritis |
| Q33611149 | Tumour necrosis factor alpha and mucocutaneous leishmaniasis |
| Q34127393 | Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications |
| Q35554897 | Tumour necrosis factor receptor gene therapy affects cellular immune responses in collagen induced arthritis in mice. |
| Q57569294 | Tumour necrosis factor α and interleukin 1β in relapse of Crohn's disease |
| Q37580905 | Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety |
| Q33588350 | Update in internal medicine |
| Q34140984 | Update on synovitis |
| Q37290628 | Update on the use of etanercept across a spectrum of rheumatoid disorders |
| Q77713039 | Update on treatment of rheumatoid arthritis |
| Q34071238 | Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis (May 2000) |
| Q34560553 | Updated consensus statement on tumour necrosis factor blocking agents for the treatment of rheumatoid arthritis and other rheumatic diseases (April 2001) |
| Q34109021 | Use of biologics in the treatment of childhood rheumatic diseases |
| Q34773482 | Use of modulators of airways inflammation in patients with CF. |
| Q47447405 | Use of volumetric computerized tomography as a primary outcome measure to evaluate drug efficacy in the prevention of peri-prosthetic osteolysis: a 1-year clinical pilot of etanercept vs. placebo |
| Q44599587 | Value of anti-TNF-alpha molecules in inflammatory and infectious diseases |
| Q73820269 | Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease |
| Q99551271 | Viromers as carriers for mRNA-mediated expression of therapeutic molecules under inflammatory conditions |
| Q53855814 | [Biologicals in treatment of rheumatoid arthritis and other inflammatory arthropathies]. |
| Q81573531 | [Etanercept] |
| Q81772569 | [Four-year observation of etanercept therapy for rheumatoid arthritis in a single German center] |
| Q73577968 | [Gene transfer immunotherapy in rheumatoid arthritis: perspectives] |
| Q73370072 | [Rheumatoid arthritis: new molecular and cellular aspects] |
| Q74042917 | [Systematic review of clinical trials on the treatment of rheumatoid arthritis with tumour necrosis factor alpha inhibitors] |
| Q84373485 | [Treatment of patients with destructive arthritis with certolizumab pegol] |
| Q73164408 | [Update of rheumatology--II. State and prospectives of chemotherapy in chronic arthritis] |
| Q73782191 | beta-Chemokine production in CD40L-stimulated monocyte-derived macrophages requires activation of MAPK signaling pathways |
Search more.